The role of MRI as a surrogate outcome measure in multiple sclerosis

H. F. McFarland, F. Barkhof, J. Antel, D. H. Miller

Research output: Contribution to journalArticle

Abstract

The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-controlled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease. The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration.

Original languageEnglish (US)
Pages (from-to)40-51
Number of pages12
JournalMultiple Sclerosis
Volume8
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Multiple Sclerosis
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Chronic Progressive Multiple Sclerosis
Clinical Trials
Pathology
Therapeutics
Central Nervous System Diseases
Physiologic Monitoring
Cost-Benefit Analysis
Placebos
Research Personnel

Keywords

  • Mri
  • Outcome measure

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

The role of MRI as a surrogate outcome measure in multiple sclerosis. / McFarland, H. F.; Barkhof, F.; Antel, J.; Miller, D. H.

In: Multiple Sclerosis, Vol. 8, No. 1, 2002, p. 40-51.

Research output: Contribution to journalArticle

McFarland, HF, Barkhof, F, Antel, J & Miller, DH 2002, 'The role of MRI as a surrogate outcome measure in multiple sclerosis', Multiple Sclerosis, vol. 8, no. 1, pp. 40-51. https://doi.org/10.1191/1352458502ms767xx
McFarland, H. F. ; Barkhof, F. ; Antel, J. ; Miller, D. H. / The role of MRI as a surrogate outcome measure in multiple sclerosis. In: Multiple Sclerosis. 2002 ; Vol. 8, No. 1. pp. 40-51.
@article{4c7822f81b3f4ab28b38c9560786eb63,
title = "The role of MRI as a surrogate outcome measure in multiple sclerosis",
abstract = "The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-controlled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease. The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration.",
keywords = "Mri, Outcome measure",
author = "McFarland, {H. F.} and F. Barkhof and J. Antel and Miller, {D. H.}",
year = "2002",
doi = "10.1191/1352458502ms767xx",
language = "English (US)",
volume = "8",
pages = "40--51",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - The role of MRI as a surrogate outcome measure in multiple sclerosis

AU - McFarland, H. F.

AU - Barkhof, F.

AU - Antel, J.

AU - Miller, D. H.

PY - 2002

Y1 - 2002

N2 - The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-controlled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease. The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration.

AB - The need for more specific and more sensitive outcome measures for use in testing new therapies in multiple sclerosis (MS) is generally accepted. This need has been accentuated by the realization that the ability to conduct large placebo-controlled trials will be limited in the future. From the first use of magnetic resonance imaging (MRI) to study MS, the ability of this imaging technique to identify areas of the central nervous system damage by the disease process in MS has been impressive. Thus, the possibility that MRI could serve as a surrogate outcome measure in clinical trials in MS has been attractive. The use of MRI as a surrogate outcome measure has been examined by an international group of investigators with expertise in clinical aspects of MS, the use of MRI in MS, and in experimental therapeutics. The group agreed that MRI does not represent a validated surrogate in any clinical form of MS. It was also agreed, however, that MRI does provide a reflection of the underlying pathology in the disease, but no single MRI measurement in isolation was seen as sufficient to monitor disease. The use for multiple imaging techniques, especially new, emerging techniques that may better reflect the underlying pathology, was seen as particularly important in monitoring studies of patients with either secondary or primary progressive MS. The choice of MRI techniques used to monitor new therapies needs to be consistent with the proposed mechanisms of the new therapy and phase of the disease. It was also noted, however, that additional validation is required for nonconventional imaging techniques. Finally, the participants noted that clinical trials using MRI as a primary outcome measure may fail to fully identify the effects of the therapy on clinical measures and that the risk and cost-benefit ratio of the treatment might be unresolved. Thus, before MRI is used as a primary outcome measure, new approaches to trial design must be given careful consideration.

KW - Mri

KW - Outcome measure

UR - http://www.scopus.com/inward/record.url?scp=0036189054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036189054&partnerID=8YFLogxK

U2 - 10.1191/1352458502ms767xx

DO - 10.1191/1352458502ms767xx

M3 - Article

C2 - 11936488

AN - SCOPUS:0036189054

VL - 8

SP - 40

EP - 51

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 1

ER -